Generation Bio

GENERATION BIO CO

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Biotech

Earnings

Earnings Misses

News

Penny Stocks

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

GBIO

HOOK

Generation Bio Co. (NASDAQ: GBIO) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.47 per share a year ago. These figures are adjusted for non-recurring items.

Generation Bio Co. Reports Q2 Loss, Tops Revenue Estimates

Intraday Update

Movers

AAOI

ADPT

Advanced Environmental Recycling Technologies

AERT

AFRM

APVO

BIOL

BLNK

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

COMM

CREV

CUTR

CWCO

DOCS

DRCT

Sunrise New Energy Co., Ltd - Ordinary Shares

EPOW

FBIO

GCTK

GDOT

GRPN

ILMN

Intelligent Bio Solutions Inc. - Common Stock

INBS

INDV

INVO

IPDN

JYNT

LILA

LOCL

LYEL

MNTK

MRAI

MTEM

MVST

NMRD

OUST

PGEN

PLUG

PRPL

RCEL

RILY

SHCO

SNCR

SPRY

SYNA

TARS

TCON

TKLF

TMCI

TSHA

TWOU

VIRI

VUZI

VZIO

WEST

WHLR

WYNN

Shares of Wynn Resorts, Limited (NASDAQ: WYNN) fell sharply on Friday after the company reported third-quarter financial results.

Why Wynn Resorts Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Pre-Market Outlook

MRIN

Shares of  Direct Digital Holdings, Inc. (NASDAQ: DRCT) rose sharply in pre-market trading after the company reported better-than-expected third-quarter financial results.

Why Direct Digital Shares Are Trading Higher By Around 33%; Here Are 20 Stocks Moving Premarket

Generation Bio Co

Press Releases

Generation Bio to Present at the 2024 TD Cowen Genetic Medicines & RNA Summit

Generation Bio to Present at the Canaccord Genuity 44th Annual Growth Conference

Generation Bio Reports Second Quarter 2024 Financial Results

Generation Bio to Present at the 2024 Cantor Global Healthcare Conference

Generation Bio Announces the Presentation of Preclinical Data on ctLNP and iqDNA at the ESGCT 31st Annual Congress

Generation Bio Reports Recent Business Highlights and Third Quarter 2024 Financial Results

Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases

Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.

Generation Bio to Present at the TD Cowen 45th Annual Health Care Conference

Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Annovis Bio

bluebird bio

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Clene

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

FibroGen

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

MiNK Therapeutics

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Longeveron

Mural Oncology

OS Therapies

Ovid Therapeutics

Passage Bio

Pluri

Q32 Bio

Rallybio

RenovoRx

Tenax Therapeutics

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

Canaccord Genuity

Needham

Wedbush

JP Morgan

Comments

Generation Bio

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga